Trial Profile

SP16 Inflammatory Response Inhibition Trial

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SP-16 (Primary)
Indications Inflammation; Myocardial infarction
Focus Therapeutic Use
Acronyms SPIRIT

Most Recent Events

01 Nov 2022 Results assessing Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 in Patients With ST-Segment Elevation Myocardial Infarctionpublished in the Journal of Cardiovascular Pharmacology
13 Jan 2022 Status changed from active, no longer recruiting to completed.
11 Mar 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com